3B Blackbio DX

3B Blackbio reported 9-month revenue of ₹99.06 croreCurrent reported value: ₹99.06 crore. No comparable prior figure is available in the source record., up 11.8% YoYCurrent reported value: 11.8% YoY. No comparable prior figure is available in the source record. (or ~20% excluding seasonal flu spikes). Excluding a one-off HAT contract of ~₹8.8 croreCurrent ₹8.8 crore. Reported change: one-off., core growth was modest. Management guided full-year top-line growth of 10-15%Current reported value: 10-15%. No comparable prior figure is available in the source record. and export growth of 15-20%Current reported value: 15-20%. No comparable prior figure is available in the source record., with EBITDA margin likely compressed due to one-time M&A expenses. The company maintains a 12-15%Current 12-15%. Reported change: flat. market share in the Indian open-system molecular diagnostics market (TAM ₹400-500 crore). Key growth drivers include the Chorus acquisition (lateral flow/AMR), UK subsidiary expansion, and upcoming US FDA filings for Chorus products. Risks include intensifying competition from players entering high-margin molecular diagnostics, lumpy HAT contract sunsetting in 2 years, and slow NGS adoption. The company is actively scouting for acquisitions with ~₹130-140 crore earmarked.